Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA6 | P23280 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 4/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8350056 | 0.86 | CA1 (0.54) | CA1CA2CA9CA12CA6 | |
| SCHEMBL48885 | 0.84 | CA2 (0.52) | CA1CA2CA9CA12CA6 | |
| Methane SCHEMBL27503773 | 0.82 | CA2 (0.50) | CA1CA2CA9CA12CA6 | |
| Hydrochloric Acid SCHEMBL6399557 | 0.82 | CA2 (0.50) | CA1CA2CA9CA12CA6 | |
| SCHEMBL207671 | 0.81 | PTGS2 (0.44) | ALOX5APFEN1PTGS2 | |
| SCHEMBL7443147 | 0.81 | PGAM1 (0.38) | CYP2C9PTGS2 | |
| SCHEMBL1080972 | 0.79 | CA2 (0.61) | CA1CA2CA9CA12CA6 | |
| SCHEMBL30940556 | 0.78 | CA1 (0.52) | CA1CA2CA9CA12CA6 | |
| SCHEMBL890792 | 0.78 | CA1 (0.52) | CA1CA2CA9CA12CA6 | |
| SCHEMBL27954274 | 0.78 | CA2 (0.65) | CA1CA2CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090836-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2008-04-17 | — | — | US | claimed |
| EP-1794130-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-06-13 | — | — | EP | claimed |
| US-20060183780-A1 | Pyrazole compounds useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2006-08-17 | — | — | US | claimed |
| WO-2006032852-A1 | PYRAZOLE COMPOUNDS USEFUL UIN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2006-03-30 | — | — | WO | claimed |
| EP-1603897-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2005-12-14 | — | — | EP | claimed |
| WO-2004080999-A1 | PYRAZOLE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2004-09-23 | — | — | WO | claimed |
| US-20030199698-A1 | Carbamic acid esters as inhibitors of factor xa | MERCK PATENT GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| EP-1925611-B1 | OPTICALLY ACTIVE DIAMINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| CN-103214414-B | The diamine derivative of opticity and manufacture method thereof | SANKYO CO. (JP) | 2016-02-17 | — | — | CN | disclosed |
| CN-103214414-A | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-07-24 | — | — | CN | disclosed |
| CN-101263110-B | Optically active diamine derivative and process for producing the same | DAIICHI SANKYO CO LTD | 2013-04-03 | — | — | CN | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-1107954-A1 | 2-OXO-$i(2H)-QUINOLINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2001-06-20 | — | — | EP | disclosed |
| CN-1268117-A | Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis | DU PONT PHARM CO (US) | 2000-09-27 | — | — | CN | disclosed |
| WO-2000051989-A1 | PYRAZOLE-3-ON-DERIVATIVE AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000040583-A2 | IMIDAZO[4,5-C]-PYRIDINE-4-ON-DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-07-13 | — | — | WO | disclosed |
| US-6043257-A | ANTICOAGULANT; PYRIDINE SUBSTITUTED INDAZOLE COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| WO-2000012479-A1 | 2-OXO-2H-QUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000008005-A2 | PIPERAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090836-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | ALOX15, ALOX15B, ALOX12 | CA1 4324/4885CA2 4029/4885CA9 4289/4885 |
| US-20030199698-A1 | Carbamic acid esters as inhibitors of factor xa | F11, F12, F13A1 | CA1 62/4885CA2 144/4885CA9 240/4885 |
| US-20060183780-A1 | Pyrazole compounds useful in the treatment of inflammation | ALOX15, ALOX12, ALOX15B | CA1 4525/4885CA2 4162/4885CA9 4584/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | CA1 2310/4885CA2 4684/4885CA9 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.